Answers are grounded in this paper and cite their sources.
Reveals metformin impedes tumor progression in hepatocellular carcinoma, suggesting a novel epitranscriptomic mechanism.
A modification and expression of Fatty acid synthase (FASN) and Acetyl-CoA carboxylase 1 (ACC1) transcripts - effects reversed by METTL3 overexpression. These findings establish METTL3 as a central mediator of metformin's metabolic and antiproliferative activities in HCC, uncovering a previously unappreciated epitranscriptomic mechanism by which metformin impedes tumor progression.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: